The potential for negative effects of cannabis use has been a topic of great interest across scientific disciplines. Cannabis is the most commonly used illicit drug in the U.S. with estimates of 17.4 million current users; an increase of 3 million since 2007 (SAMSHA, 2011) . In addition to those using cannabis illicitly, millions of additional individuals consume the drug for medical reasons. As of the end of 2011, 16 states in the U.S. had medical marijuana laws in effect, and many other states were seeking similar legislation. With the number of cannabis users both illicitly and licitly increasing, the question of any potential lasting impact from cannabis use is increasingly important.
While cannabis consists of a large number of cannabinoids, delta-9-tetrahydrocannabinol (typically referred to as "THC" among users, and "⌬-9-THC" among scientists) is the compound thought to be the primary source of effects experienced by users (Grotenhermen, 2003) as well as the likely cause of lasting cognitive effects, if any lasting effects exist. During acute cannabis intoxication, several neurocognitive effects have been regularly identified including effects on learning and memory performance, with mixed evidence for effects on attention, inhibition, and executive functioning (for reviews see Crean, Crane, & Mason, 2011; Gonzalez, 2007; Ranganathan & D'Souza, 2006) . While acute intoxication can last several hours, THC is also a fat soluble compound that can be stored in body fat and slowly released into the bloodstream for months (Ellis, Mann, Judson, Schramm, & Taschian, 1985; Grotenhermen, 2003) . This characteristic is one element that has encouraged research evaluating potential "residual" neurocognitive effects.
"Residual effects" are those effects observed after acute intoxication has passed, and early attempts to measure residual neurocognitive effects of cannabis use resulted in mixed findings. Several studies were unable to find cognitive effects among moderate to heavy cannabis users (Bowman & Pihl, 1973; Carlin & Trupin, 1977; Grant, Rochford, Fleming, & Stunkard, 1973) . Other studies, however, found residual effects on verbal memory, attention, speed and accuracy, and perceptual-motor tasks among cannabis users when compared to controls (Entin & Goldzung, 1973; Fletcher et al., 1996; Soueif, 1976; Varma, Malhotra, Dang, Das, & Nehra, 1988) . In a review of empirical literature on residual effects of cannabis, major methodological problems afflicting most of the existing research were identified and may explain these seemingly inconsistent findings (Pope, Gruber, & Yurgelun-Todd, 1995) . Problems included failure to specify the abstinence period, confounding variables poorly controlled for (e.g., other drug use, psychiatric symptoms), and testing of participants was not always blind. In addition, the authors emphasized the need to distinguish between two types of potential "residual" effects; active THC metabolites that affect the CNS; and effects that persist after THC and active metabolites have left the body. Overall, the authors concluded that there was a lack of sufficient research into lasting cognitive impacts of cannabis use to draw any conclusions (Pope et al., 1995 p.32) . More recent reviews, however, have concluded that there may be evidence for lasting detrimental effects (e.g., Crean et al., 2011; Solowij & Battisti, 2008) . Narrative reviews are inherently limited by the subjectivity of their conclusions and estimates of magnitude and consistency of effects cannot be made (Borenstein, Hedges, Higgins, & Rothstein, 2009) . Meta-analysis addresses narrative review limitations by statistically synthesizing data using effect sizes from multiple studies to calculate a summary effect (Borenstein et al., 2009 ). To date, only one meta-analysis has been focused on evaluating residual neurocognitive effects of cannabis use (Grant, Gonzalez, Carey, Natarajan, & Wolfson, 2003) . Using selection criteria that addressed a number of the concerns enumerated by Pope et al. (1995) , a global neuropsychological effect, as well as a summary effect for eight neuropsychological domains of functioning were calculated: abstraction/executive, attention, simple reaction time (RT), verbal/language, perceptual-motor, simple motor, learning, and forgetting/retrieval. Results of the meta-analysis revealed a small yet significant effect for global performance, and across domains, only revealed significant negative effects for learning and forgetting/retrieval. However, the abstention period for users across most studies was 72 hours or less prompting the authors to suggest that differences observed may have been largely attributable to the type of residual effect associated with drug residue in the users system instead of being indicative of lasting effects. One included study highlighting the importance of this distinction tested users and nonusers across a 28-day period of abstention and found that while differences were observed in the initial days of abstinence, these differences were no longer significant at Day 28 (Pope, Gruber, Hudson, Huestis, & Yurgelun-Todd, 2001 . Overall, there were not enough studies at that time that measured the type of residual effects indicative of a permanent or very long-term impact on cognitive functioning.
In the present study, two meta-analyses of the empirical literature on cannabis-related residual effects on neurocognitive performance were conducted. First, we updated a previous meta-analysis on broad nonacute cognitive effects of cannabis use through inclusion of newer studies. In a second meta-analysis, we focused on evidence for lasting residual effects by including only studies that tested users after at least 25 days of abstinence. In order to increase generalizability across both investigations, the same rigorous selection criteria were used and effects were summarized globally as well as across the eight neuropsychological domains described previously. It is hypothesized that across all studies, there will be an inverse relationship between abstention time and impact on neurocognitive abilities such that the evidence of negative residual effects on cognitive performance among cannabis users, will disappear when looking at studies with a longer abstention period.
Method
In order to identify all relevant studies, a literature search was conducted using the online databases PsycInfo, PsycARTICLES, PubMed, and Medline. The search terms used were (marijuana or marihuana or tetra-hydrocannabinol or THC or cannabis) AND (neuro* or cognit* or assess* or abilit* or effect* or process* or impair*) AND (residual or long-term or abstinen* or abstain* or lasting or non-acute or persist*). Results were additionally limited to those published in a peer-reviewed journal and to those involving human subjects. The requirement of peer-review was put in place to increase transparency and replicability of results and to ensure studies included have met a minimum degree of methodological rigor (Rosenthal & DiMatteo, 2001 ). The resulting ϳ800 citations were evaluated for relevance by review of the title and abstract. The full-text of articles deemed relevant was obtained as well as those for which relevance could not be determined. The references of each full-text article obtained were reviewed for identification of additional studies missed during the database searches. This resulted in a total of 186 full-text articles to be reviewed for inclusion. The articles retained were then reviewed in more detail and categorized broadly based on their relevance. This process resulted in the elimination of 37 articles which were reviews; 25 articles which evaluated acute effects only or in which it was not specified; 13 articles which were brain imaging studies not including neuropsychological measures; 10 articles which were deemed not relevant (i.e., animal studies, case studies, effects of prenatal exposure, effects on emotional processing); and two which were evaluating specific psychiatric populations (i.e., schizophrenia and Tourette's syndrome).
The remaining studies were then reviewed for inclusion using the criteria detailed by Grant, Gonzalez, Carey, Natarajan, and Wolfson (2003) : (a) study included a group of cannabis only users, (b) study included a control group consisting of nonusers or with very limited drug experience, (c) study reported necessary information to calculate effect size, (d) study used a valid behavioral measure of neuropsychological functioning, (e) participants are not under the influence of any substances during testing, (f) the use of other substances (past and present) is addressed, (g) history of psychiatric and neurological problems is addressed, (h) the period of abstinence from cannabis before testing is reported. These criteria were selected as they ensure the results of each study are sufficiently answering the research question and also to allow for generalizability across both meta-analyses. A total of 49 studies met all inclusion criteria. One study, Skosnik, Krishnan, Vohs, and O'Donnell (2006) reported results for males and females separately, and therefore these were treated as independent samples. There were also nine studies which shared a sample with another study meeting inclusion criteria. In these instances the samples were not treated as independent and instead combined within the metaanalysis (e.g., Pillay et al., 2004 Pillay et al., , 2008 Pope et al., 2001 Pope et al., , 2002 Pope et al., , 2003 all shared participants). Also, due to the significant increase in the number of studies meeting inclusion criteria and in efforts to avoid redundancy with the previous meta-analysis, the present study focused on studies published since 2000. For the overall meta-analysis, this resulted in a final set of 33 independent samples with data from 1,010 current or former cannabis users and 839 controls with no or very limited cannabis use history (see Table 1 for additional information regarding the samples of each included study). Of the total 33 studies meeting inclusion, 13 measured neurocognitive performance after approximately one month of absti-2 Table 1 33 Independent Samples Meeting Inclusion Criteria Meta-analysis was conducted using Comprehensive MetaAnalysis Version 2.0 (CMA), a computer program that allows for the computation of multiple effect sizes from a variety of reported data formats (Borenstein, Hedges, Higgins, & Rothstein, 2005) . In the present analysis, data was extracted from the primary studies to compute Hedge's g. This effect size measure was selected over the commonly used standardized mean difference due to the large number of studies with small sample sizes included. Hedge's g is calculated with a correction for the overestimation of effect that can occur in small sample when using Cohen's d (Borenstein et al., 2009) . CMA also allows for consideration of multiple comparisons within a sample (i.e., heavy users vs. controls and moderate users vs. controls) as well as multiple outcomes. A majority of the studies included reported multiple outcomes across a number of neuropsychological measures. CMA allows for the combination of the effect sizes by averaging across different outcomes within a study to derive a synthetic or summary effect estimate. Thus, an overall neurocognitive performance effect for each study was calculated to evaluate the evidence of a global effect. Due to the lack of overlap in measures across studies, the guidelines for categorizing outcomes described by Grant et al. (2003) were used to also arrive at eight neurocognitive domains for evaluation. These domains were selected in order to be appropriately broad (so as to have a sufficient number of studies falling into each), as well as to allow for generalizability with Grant et al.'s (2003) findings. See Table 2 for descriptions of the domains and examples of measures falling into each.
In order to evaluate variance in effect sizes across studies, the Q statistic and I 2 were calculated as tests for heterogeneity. A significant Q statistic would indicate that the true effects vary across studies due to multiple population parameters. I 2 is a measure of the proportion of observed variance that is indicative of true effect size differences and is not impacted by the number of studies included (while Q is). It reflects the overlap of study effect size confidence intervals, with a large I 2 value reflective of high inconsistency across studies. Lastly, as studies with significant results are more likely to be published and several studies only reported sufficient information for significant results within the study, the fail safe N was calculated for significant results. The fail safe N determines the number of studies needed with effect sizes of zero to change the significance of the summary effect size (Borenstein et al., 2009) .
Given the degree of variability present in the included studies (abstinence length, outcome measures, population characteristics, etc.) a random-effects model was selected. A random-effects model assumes that the true effect size varies between studies included in a meta-analysis. Thus, it is a more conservative approach as it accounts for these likely variations in the true effect sizes of different studies (Borenstein et al., 2009 ). In addition, it allows for the generalization of results to a wider population. A random-effects model was therefore deemed the more appropriate and preferred model. Table 1 ( Only participants in the THCϪsubgroup were included in the 13 study meta-analysis.
‫ء‬
Study included in both 33 and 13 study meta-analysis.
Ϯ
Studies shared sample participants and therefore were combined and treated as one independent sample.
⌿
Study used an adolescent sample.
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Results
Studies-Meta-Analysis Overall Residual Effects
The global effect size for all assessed cognitive domains indicated a significant negative effect, ES ϭ Ϫ0.29 CI 95% [Ϫ0.46 to Ϫ0.12] p Ͻ .001. The summary effect sizes for each study ranged from Ϫ1.28 -1.83 and as expected there was significant heterogeneity across study effect sizes, Q (32) ϭ 78.54, p Ͻ .001, I
2 ϭ 59.26, T 2 ϭ 0.13. The summary effect sizes and heterogeneity statistics for the eight measured domains are presented in Table 3 . For most of the cognitive domains, there was also a significant negative effect size indicating cannabis related decrease in performance. However, for perceptual-motor and simple RT the effect sizes were not significant. For both domains the summary effects were positive with the 95% confidence intervals including zero. There was also significant heterogeneity for most of the domains with the exception of Abstraction/Executive, Motor, and Perceptual-motor functioning. Overall, the results indicate a small negative residual effect of cannabis use on neuropsychological performance, with significant variability across studies. This negative effect was not evident for the domains of perceptual-motor functioning and simple RT. The fail safe N for the overall effect size was 256 studies. This indicates that 256 studies with an effects size of zero would need to be included in the analysis in order to accept the null hypothesis.
Studies-Meta-Analysis Lasting Residual Effects
For studies with at least 1-month of abstinence, a global effect size for all assessed cognitive domains was calculated. The global effect was not significant with zero falling within the confidence interval [ES ϭ Ϫ0.12, CI 95% [Ϫ0.32 to 0.07] p ϭ .22] indicating no evidence for lasting residual effects on overall performance. Similarly, for all eight of the measured cognitive domains, the summary effect size was not significant, including zero within the 95% confidence interval. The study results for each domain are presented in Figure 1 . Tests of heterogeneity were not significant for the global neurocognitive effect size [Q (12) ϭ 17.93, p ϭ .12, I 2 ϭ 33.09, T 2 ϭ 0.04] or for any of the eight cognitive domains.
Overall, results indicate no lasting residual effects of cannabis use on neuropsychological performance.
Metaregression
As both meta-analyses included studies using either exclusively adolescent or adult samples, the potential that age and duration of use moderated observed effect sizes was evaluated. Separate metaregression analyses were conducted for continuous variables of age and duration using the method of unrestricted maximum likelihood for random effects regression (Borenstein et al., 2009) . Results showed that neither age nor duration of use were significant moderators for either the 33 study or 13 study meta-analyses.
Discussion
The present investigation used meta-analytic methods to evaluate the presence of residual neurocognitive effects from cannabis use. Two separate analyses were conducted in order to determine whether observed effects were due to drug residue (the presence of metabolites still acting in the CNS) or due to lasting effects on cognitive performance. The first analysis included all 33 studies meeting inclusion criteria and revealed evidence of a small but significant effect both globally and for six of the eight neurocognitive domains. Perceptual-motor and simple RT were the exceptions with positive effect sizes and confidence intervals including zero, indicating no significant observable effect. Therefore, results indicate evidence for small neurocognitive effects that persist after the period of acute intoxication. The second meta-analysis included only the 13 studies whose abstention period was at least 25 days. Results for this analysis revealed no evidence of a significant effect on neurocognitive performance. For the global summary effect and all the cognitive domains measured, the effects sizes all had confidence intervals including zero indicating no evidence of lasting effects on cognitive performance due to cannabis use.
This 33 study meta-analysis expands on the prior meta-analytic investigation into the residual effects of cannabis use (Grant et al., 2003) . We were able to replicate the observed negative effects reported for global neurocognitive performance, learning, and forgetting/retrieval as well as replicate the failure to identify duration (Gansler, Jerram, Vannorsdall, & Schretlen, 2011) .
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of use as a significant moderator variable. The current results also reveal additional negative effects in the domains of abstraction/ executive functioning, attention, verbal/language, and motor functioning. These differences may reflect the large increase in studies meeting inclusion criteria as the chances of committing a Type II error due to insufficient power are reduced with a larger number of primary studies (Borenstein et al., 2009 ). In addition to increased power, the negative effects observed in the present meta-analysis are strengthened by the more conservative approach taken (i.e., use of random-effects model and presumed high correlation between measures) which results in larger confidence intervals and subsequently makes it more difficult to reject the null hypothesis. However, it is important to consider the distinction between statistical significance and clinical significance. Although small to moderate negative effect sizes are observed, it remains unclear whether these differences translate into practical impairments in functioning (Grant et al., 2003) . In addition, these effects do not appear to persist beyond the first 25 days after acute intoxication. While a residual effect of cannabis use is consistent with the results, a potential withdrawal effect provides an alternative explanation that must be addressed (Grant et al., 2003; Pope et al., 2001) . The participants across studies consisted of moderate to heavy cannabis users evaluated over a wide range of abstention periods. However, most users were evaluated somewhere between 4 hrs and 10 days of abstention. This is problematic because in heavy users, cannabis withdrawal symptoms (e.g., irritability, aggression, anxiety, restlessness, etc.) have been shown to peak between Days 2 and 6 of cessation and to last anywhere from 4 to 14 days (Budney, Moore, Vandrey, & Hughes, 2003) . These experienced symptoms could therefore impact and explain subsequent performance differences on outcome measures. Despite a majority of studies addressing this potential confound within the discussion of their results, only four independent samples reporting abstention periods of less than 25 days actually measured and accounted for withdrawal symptoms in their study design (Battisti et al., 2010a (Battisti et al., , 2010b Hester, Nestor, & Garavan, 2009; Pope et al., 2001; Solowij et al., 2002) . The inability to discriminate between these competing explanations of results in half of the primary studies carries over to interpretation of the 33 study meta-analysis results. Therefore, it is unclear whether the observed effect sizes reflect evidence of a cannabis residue effect, the effects of cannabis withdrawal, or both. The likelihood of withdrawal effects impacting the results is greatly reduced in the 13 study metaanalysis that only included data collected after abstention periods of 25 days or longer.
As hypothesized, the meta-analysis conducted on studies evaluating users after at least 25 days of abstention found no residual effects on cognitive performance. Effect sizes failed to reach significance across all domains and the heterogeneity between studies present in the first meta-analysis greatly reduced. These results fail to support the idea that heavy cannabis use may result in long-term, persistent effects on neuropsychological functioning. To fully understand these results, however, several potential limitations must be noted. First, these findings are based on 13 studies, and interpretation of these results should be commensurate with the number of studies included. Second, across the 13 studies, mean ages were variable, ranging from 17 to 47 years, with wide ranges of frequency and duration of use. In addition, six of the 13 studies included in this second meta-analysis used adolescent samples exclusively. While frequency of use could not be evaluated due to the high diversity in reporting metric (e.g., days per week, joints per week, cones per week, lifetime episodes, etc.), investigation of potential moderators failed to support age or duration of use as variables impacting observed effect sizes. However, five of the studies using adolescent samples did not report duration and it is unclear whether these samples were comparable to those reporting this variable. As such, further research is needed to evaluate whether duration of use is a potential moderator for effects seen after 25 days of abstinence. There is also some evidence that an earlier age of onset for cannabis use may be related to poorer neurocognitive performance (Pope et al., 2003) . It may be that lasting residual effects of cannabis use are dependent on onset of regular use occurring before a certain age or developmental stage. Therefore, caution should be used in generalizing these results to potential subpopulations of cannabis users such as those with an early age of onset or with more chronic durations of use. As discussed by Grant et al., (2003) , another important consideration is the lack of information regarding users' premorbid performance. It is difficult to interpret scores as notable changes resultant from their cannabis use when their capabilities before onset are unknown. Grant et al., (2003) discusses the possibilities of longitudinal designs as well as twin studies to try and address these issues. Studies utilizing both these methodologies have been published since these issues were raised. Two longitudinal studies examining changes in IQ and specific neurocognitive domains reported negative effects in performance in current heavy cannabis users, but not in former heavy users (Fried, Watkinson, & Gray, 2005; Fried, Watkinson, James, & Gray, 2002) . While no specific abstention period was reported for current users (just indications that intoxication was unlikely), former users had not used for at least 3 months. These longitudinal studies were not included in the present study because neither study addressed potential psychiatric or neurological problems. The results of these investigations, however, remain consistent with the present findings which reveal no long-term effects of cannabis use on neurocognitive performance.
While longitudinal studies allow for measurement of premorbid abilities, monozygotic twin studies allow for control of potential genetic confounds (Grant et al., 2003; Lyons et al., 2004) . To date, only one twin study has been conducted looking at the effects of cannabis use on neuropsychological performance. The study compared a participant with a history of regular cannabis use to their monozygotic twin (who had no history of use) on a large neuropsychological battery (Lyons et al., 2004) . Within the extensive battery of measures given to the twin pairs, the only significant difference found was on the block design subtest of the WAIS-R. This twin study is included in both the full 33 study meta-analysis and the 13 study meta-analysis as the abstention period for the cannabis using twin was a minimum of 1 year (although the mean was approximately 20 years). The results of this well-matched study again remain consistent with the outcome of the present study, which indicate no evidence of a long-term effect of cannabis use on neurocognitive performance.
One limitation inherent in the research design of the present meta-analysis is the large number of combinations performed to arrive at summary effect sizes. This injects a considerable amount of complexity into the results which can confuse interpretation and potentially obscure findings (Grant et al., 2003) . While a global effect size for neurocognitive performance is reported, it is important to note that the specific domain effects size should also be viewed as global. In other words, the reported effect size for Figure 1 . Forest plots for the eight assessed neurocognitive domains. Each domain plot depicts results from both the 33 and 13 study meta-analyses with summary effects at the bottom of each plot. Numeric notations labeling separate effect sizes refer to the independent samples as numbered in Table 1. attention is a summary of a number of different outcome measures of attention. Although a significant negative effect size was found for global attention in the 33 study meta-analysis that is not to say this result would generalize to a more specific measure of attention (e.g., divided attention, sustained attention, etc.). These metaanalyses evaluated the presence of a systematic residual effect on cognitive performance within the literature and interpretation of results to more specific outcomes is beyond the scope of the present study. Future research into the residual effects of cannabis use on neurocognitive performance should focus on continuing to control for important confounds. Most notably, for study designs consisting of abstention periods of less than one month, withdrawal symptoms need to be assessed for and included in subsequent analyses. A majority of the studies on residual effects of cannabis use cannot draw reasonable conclusions about the cause of any observed effects due to this potential confound not being adequately addressed. More evaluations with longer term periods of abstinence are also needed. Although inherently more difficult, studies utilizing monitored abstinence with drug testing would greatly strengthen the literature. Very few of the primary studies were able to conduct monitored abstinence and drug testing. Instead most designs depended on self-reports of cannabis abstinence which increases the potential for error in study conclusions. It may also be beneficial to take the emphasis off abstinence periods, and instead rely on metabolite concentrations when available. Given the unpredictability in strength and potency of the cannabis subjects are using and individual differences in duration and frequency of use, a set number of days abstaining may result in extremely varied metabolite concentrations for different users (Grotenhermen, 2003; Pope et al., 1995) . When possible, the assessing and reporting of metabolite concentrations would provide greater information about the role actual drug residue may play in any observed neurocognitive effects.
In sum, two separate meta-analyses were conducted to evaluate the evidence for residual effects on cognitive performance as a result of cannabis use. The first evaluated all investigations into nonacute cognitive performance, while the second aimed to assess whether cannabis use resulted in long-term, lasting effects. While the first meta-analysis revealed a small significant negative effect for general performance and a number of cognitive domains, the clinical significance remains unclear. In addition, primary study designs preclude definitive conclusions as to whether observed results are due to residual effects of cannabis use or due to cannabis withdrawal symptoms. A second meta-analysis focusing on studies with longer abstention periods was conducted and indicated no lasting residual effects on neurocognitive performance as a result of cannabis use. Taken together, the results help to clarify the seemingly inconsistent results present in the literature. Discrepant findings may not be discrepant at all but instead reflect difference in effect size due to variable periods of abstention across studies. Whether differences seen in the initial days or weeks of abstinence are due to drug residue effects or withdrawal effects, after approximately 1 month these effects do not persist for the moderate to heavy user.
